Dunedin-based biomedical company Pacific Edge has signed an agreement with Australian health care provider Healthscope to market its test for the detection of bladder cancer.
Under the deal, Healthscope Pathology would market and offer laboratory services to urologists and general practitioners for the detection of bladder cancer using Cxbladder in Australia, Pacific Edge said today.
Pacific Edge would provide services to New Zealand urologists and GPs through its subsidiary Pacific Edge Diagnostics NZ, with its diagnostic laboratory based in Dunedin.
It would retain the rights to the rest of the world for the marketing of Cxbladder.
Terms of the licence agreement were confidential.
Cxbladder was a non-invasive, accurate test that enabled the early detection of bladder cancer from a small volume of urine, Pacific Edge said.
It provided a quick, cost effective and accurate measure of the presence of the cancer, and could reduce reliance on the need for invasive tests such as cystoscopy.
Products in development and in clinical trials included tools for detecting and managing gastric, bladder, colorectal, endometrial cancers and melanoma, Pacific Edge said.
Its shares were up 0.5c by late morning to 20c.